Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Method of regulating cell metabolism or physiology
Patent
1999-06-25
2000-04-25
Elliott, George C.
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Method of regulating cell metabolism or physiology
536 245, C12N 1585
Patent
active
060543167
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of Ets-2. The compositions comprise antisense com ounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Ets-2. Methods of using these compounds for modulation of Ets-2 expression and for treatment of diseases associated with expression of Ets-2 are provided.
REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
Xian-Ming, Huang; Shu-guang, Wei; Lin-Fang, Wang "Reversal of Malignant Phenotype of Human Hepatoma Cells by Antisense c-ets-2, c-myc & N-ras" Zhonghua Zhongliu Zhi 16(4) 243-246, 1994.
James "Towards Gene Inhibition Therapy" Antiviral Chemistry & Chemotherapy (1991) 2(4), 191-214.
Stanley Crooker and Bernard LeBleu "Antisense Research and Applications" Ch 15, 273-288 1993.
Milner, Natalie; Mir, Kalsmy Southern, Edwin "Selecting Antisense Reagents on Combinatorial Oligonucleotide Arrays" Nature Biotechnology, 15, 1997, 537-541.
Bhat et al., Temporal and tissue-specific expression of mouse ets genes, Proc. Natl. Acad. Sc.i U. S. A., 1987, 84:3161-3165.
Dittmer et al., Ets transcription factors and human disease, Biochim. Biophys. Acta, 1998, 1377:F1-11.
Dooley et al., Constitutive expression of c-fos and c-jun, overexpression of ets-2, and reduced expression of metastasis suppressor gene nm23-H1 in rheumatoid arthritis, Ann. Rheum. Dis., 1996, 55:298-304.
Liao et al., Expression of the c-jun, jun-B, ets-2 and liver regeneration factor-1 (LRF-1) genes during promotion and progression of rat liver carcinogenesis in the resistant hepatocyte model, Cancer Lett., 1996, 100:215-221.
Santoro et al., Amplification of ETS2 oncogene in acute nonlymphoblastic leukemia with t(6;21;18), Cancer Genet. Cytogenet., 1992, 58:71-75.
Sapi et al., Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 0 breast carcinoma cells, Cancer Res., 1998, 58:1027-1033.
Simpson et al., Altered expression of Erg and Ets-2 transcription factors is associated with genetic changes at 21q22.2-22.3 in immortal and cervical carcinoma cell lines, Oncogene, 1997, 14:2149-2157.
Sumarsono et al., Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice, Nature, 1996, 379:534-537.
Watabe et al., The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor, Int. J. Cancer, 1998, 77:128-137.
Watson et al., Mammalian ets-1 and ets-2 genes encode highly conserved proteins, Proc. Natl. Acad. Sci. U.S.A., 1988, 85:7862-7866.
Baker Brenda F.
Cowsert Lex M.
Elliott George C.
Isis Pharmaceuticals , Inc.
Lacourciere Karen A.
LandOfFree
Antisense inhibition of ETs-2 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense inhibition of ETs-2 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense inhibition of ETs-2 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-992581